OSR1

Summary

OSR1 (odd-skipped related transcription factor 1, HGNC:8111) is a protein-coding gene on chromosome 2p24.1, encoding Protein odd-skipped-related 1 (Q8TAX0). Transcription factor that plays a role in the regulation of embryonic heart and urogenital development.

Enables sequence-specific double-stranded DNA binding activity. Involved in negative regulation of transporter activity; positive regulation of gastrulation; and pronephros development. Located in nucleus.

Source: NCBI Gene 130497 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Disputed, ClinGen)
• GWAS associations: 14
• Clinical variants (ClinVar): 44 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_145260

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8111
Approved symbol	OSR1
Name	odd-skipped related transcription factor 1
Location	2p24.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143867
Ensembl biotype	protein_coding
OMIM	608891
Entrez	130497

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000272223, ENST00000487581, ENST00000498844, ENST00000852234, ENST00000852235, ENST00000852236, ENST00000946722, ENST00000946723, ENST00000946724, ENST00000946725

RefSeq mRNA: 1 — MANE Select: NM_145260 NM_145260

CCDS: CCDS1694

Canonical transcript exons

ENST00000272223 — 3 exons

Exon	Start	End
ENSE00001001053	19353141	19353837
ENSE00001184687	19358341	19358623
ENSE00001184696	19351485	19352410

Expression profiles

Bgee: expression breadth ubiquitous, 164 present calls, max score 96.34.

FANTOM5 (CAGE): breadth broad, TPM avg 0.4552 / max 16.9462, expressed in 270 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
27060	13.2921	925
27059	0.2878	182
27057	0.0905	37
27058	0.0769	34

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
descending thoracic aorta	UBERON:0002345	96.34	gold quality
thoracic aorta	UBERON:0001515	96.02	gold quality
ascending aorta	UBERON:0001496	96.01	gold quality
aorta	UBERON:0000947	93.83	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.40	gold quality
lower esophagus	UBERON:0013473	93.28	gold quality
popliteal artery	UBERON:0002250	92.39	gold quality
tibial artery	UBERON:0007610	92.37	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	91.98	gold quality
right coronary artery	UBERON:0001625	89.91	gold quality
omental fat pad	UBERON:0010414	89.76	gold quality
peritoneum	UBERON:0002358	89.63	gold quality
adipose tissue of abdominal region	UBERON:0007808	88.46	gold quality
minor salivary gland	UBERON:0001830	87.75	gold quality
left coronary artery	UBERON:0001626	87.39	gold quality
mucosa of stomach	UBERON:0001199	87.10	gold quality
coronary artery	UBERON:0001621	86.65	gold quality
muscle layer of sigmoid colon	UBERON:0035805	86.31	gold quality
urinary bladder	UBERON:0001255	86.27	gold quality
saliva-secreting gland	UBERON:0001044	86.20	gold quality
upper lobe of left lung	UBERON:0008952	83.56	gold quality
mouth mucosa	UBERON:0003729	83.34	gold quality
upper lobe of lung	UBERON:0008948	82.58	gold quality
right atrium auricular region	UBERON:0006631	81.93	gold quality
smooth muscle tissue	UBERON:0001135	81.28	gold quality
cardiac atrium	UBERON:0002081	80.50	gold quality
adipose tissue	UBERON:0001013	79.79	gold quality
gall bladder	UBERON:0002110	79.78	gold quality
vagina	UBERON:0000996	79.68	gold quality
apex of heart	UBERON:0002098	79.64	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.17
E-CURD-10	no	2.44

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA1542.1	OSR1	Other factors with up to three adjacent zinc fingers
MA1542.2	OSR1	Other factors with up to three adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:29084951

miRNA regulators (miRDB)

81 targeting OSR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514

Literature-anchored findings (GeneRIF, showing 12)

• first report on molecular cloning and characterization of human OSR1 (PMID:12119563)
• OSR1 is expressed in human mesenchymal stem cells, the blastemal component of Wilms tumors and CD24+/CD133+ progenitor cells isolated from the mature kidney. (PMID:21821672)
• OSR1 acts as a functional tumour suppressor in gastric cancer (PMID:24931004)
• The findings of the present study showed, for the first time, the role of the OSR1 rs12329305 polymorphism in the development of congenital malformations in cases of stillborn/neonatal death. (PMID:25164089)
• In summary, our study implicated a gene network involving Tbx5, Osr1 and Pcsk6 interaction in second heart field for atrial septation, providing a molecular framework for understanding the role of Tbx5 in congenital heart disease ontogeny. (PMID:26744331)
• OSR1 was downregulated in RCC cells by promoter methylation. OSR1 can function as a tumor suppressor via inhibition of invasion and proliferation in RCC cells, possibly via upregulating tumor suppressor genes and downregulating oncogenes. (PMID:28404905)
• OSR1 was sequenced in 186 children with primary vesicoureteric reflux, and 17 have single nucleotide polymorphisms (PMID:28724605)
• Kir2.1 and Kir2.3, are activated by OSR1 through a motif variant, R-x-F-x-V/I. (PMID:29581290)
• Odd-skipped related 1 (OSR1) downregulated the activity of the Wnt signaling pathway by suppressing the expression of sex-determining region Y-box 9 (SOX9) and beta-catenin. (PMID:29660200)
• OSR1 inhibited TSCC cell migration and invasion through inhibiting NF-kappaB pathway (PMID:30244004)
• Odd-skipped related 1 plays a tumor suppressor role in ovarian cancer via promoting follistatin-like protein 1 transcription. (PMID:35964260)
• OSR1 disruption contributes to uterine factor infertility via impaired Mullerian duct development and endometrial receptivity. (PMID:37847567)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	osr1	ENSDARG00000014091
mus_musculus	Osr1	ENSMUSG00000048387
rattus_norvegicus	Osr1	ENSRNOG00000004210
drosophila_melanogaster	drm	FBGN0024244
caenorhabditis_elegans		WBGENE00003845

Paralogs (1): OSR2 (ENSG00000164920)

Protein

Protein identifiers

Protein odd-skipped-related 1 — Q8TAX0 (reviewed: Q8TAX0)

All UniProt accessions (1): Q8TAX0

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that plays a role in the regulation of embryonic heart and urogenital development.

Subcellular location. Nucleus.

Tissue specificity. Expressed in adult colon, small intestine, prostate, testis, and fetal lung.

Similarity. Belongs to the Odd C2H2-type zinc-finger protein family.

RefSeq proteins (1): NP_660303* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050717	C2H2-ZF_Transcription_Reg	Family

Pfam: PF00096

UniProt features (6 total): zinc finger region 3, chain 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TAX0-F1	60.59	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 116

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9761174	Formation of intermediate mesoderm
R-HSA-9830364	Formation of the nephric duct

MSigDB gene sets: 331 (showing top): ATF_B, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_NEGATIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_URETER_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, MYOGENIN_Q6, GOBP_METANEPHROS_DEVELOPMENT, TGCGCANK_UNKNOWN, GOBP_CARTILAGE_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_SODIUM_ION_TRANSPORT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_LIPID

GO Biological Process (52): negative regulation of transcription by RNA polymerase II (GO:0000122), urogenital system development (GO:0001655), ureteric bud development (GO:0001657), mesonephros development (GO:0001823), chondrocyte differentiation (GO:0002062), pattern specification process (GO:0007389), heart development (GO:0007507), gonad development (GO:0008406), positive regulation of gene expression (GO:0010628), cell differentiation (GO:0030154), positive regulation of bone mineralization (GO:0030501), negative regulation of epithelial cell differentiation (GO:0030857), negative regulation of transmembrane transport (GO:0034763), embryonic forelimb morphogenesis (GO:0035115), embryonic hindlimb morphogenesis (GO:0035116), sodium ion transmembrane transport (GO:0035725), embryonic skeletal limb joint morphogenesis (GO:0036023), middle ear morphogenesis (GO:0042474), odontogenesis (GO:0042476), embryonic digit morphogenesis (GO:0042733), negative regulation of apoptotic process (GO:0043066), positive regulation of transcription by RNA polymerase II (GO:0045944), intermediate mesoderm development (GO:0048389), pronephros development (GO:0048793), stem cell differentiation (GO:0048863), positive regulation of epithelial cell proliferation (GO:0050679), roof of mouth development (GO:0060021), embryonic skeletal joint morphogenesis (GO:0060272), cellular response to retinoic acid (GO:0071300), metanephric mesenchyme development (GO:0072075), cell proliferation involved in kidney development (GO:0072111), metanephric mesenchyme morphogenesis (GO:0072133), mesangial cell development (GO:0072143), metanephric mesenchymal cell differentiation (GO:0072162), posterior mesonephric tubule development (GO:0072166), specification of anterior mesonephric tubule identity (GO:0072168), specification of posterior mesonephric tubule identity (GO:0072169), mesonephric duct morphogenesis (GO:0072180), negative regulation of nephron tubule epithelial cell differentiation (GO:0072183), renal vesicle progenitor cell differentiation (GO:0072184)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), transporter inhibitor activity (GO:0141110), sequence-specific double-stranded DNA binding (GO:1990837), metal ion binding (GO:0046872)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), cytosol (GO:0005829), cell cortex (GO:0005938)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Gastrulation	1
Kidney development	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
embryonic limb morphogenesis	4
regulation of transcription by RNA polymerase II	2
animal organ development	2
embryonic morphogenesis	2
cellular anatomical structure	2
cytoplasm	2
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
system development	1
renal system development	1
mesonephric tubule development	1
kidney development	1
cell differentiation	1
cartilage development	1
multicellular organism development	1
multicellular organismal process	1
circulatory system development	1
development of primary sexual characteristics	1
reproductive structure development	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
cellular developmental process	1
bone mineralization	1
regulation of bone mineralization	1
positive regulation of ossification	1
positive regulation of biomineral tissue development	1
epithelial cell differentiation	1
regulation of epithelial cell differentiation	1
negative regulation of cell differentiation	1
regulation of transmembrane transport	1
negative regulation of cellular process	1
negative regulation of transport	1
transmembrane transport	1
forelimb morphogenesis	1
hindlimb morphogenesis	1
sodium ion transport	1
monoatomic cation transmembrane transport	1
limb joint morphogenesis	1
embryonic skeletal joint morphogenesis	1

Protein interactions and networks

STRING

572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OSR1	PRRX1	P54821	540
OSR1	PAX2	Q02962	441
OSR1	TAPT1	Q6NXT6	435
OSR1	TWIST2	Q8WVJ9	427
OSR1	BMPR1A	P36894	410
OSR1	LGALS4	P56470	404
OSR1	SIX2	Q9NPC8	399
OSR1	MEIS1	O00470	387
OSR1	SRRT	Q9BXP5	376
OSR1	TGIF1	Q15583	372
OSR1	MEOX2	P50222	370
OSR1	SMAD6	O43541	366
OSR1	LHX1	P48742	364
OSR1	NR2C2	P49116	353
OSR1	HOXD9	P28356	343

IntAct

0 interactions, top by confidence:

BioGRID (6): OSR1 (Reconstituted Complex), VHL (Affinity Capture-Western), EGLN1 (Affinity Capture-Western), OSR1 (Affinity Capture-Western), VHL (Affinity Capture-Western), EGLN1 (Affinity Capture-Western)

ESM2 similar proteins: A0JPB4, A0PJY2, B0K011, O08876, O15090, O57415, O62651, O70237, O75626, O95863, P19544, P22561, P41183, P49952, P55878, P86413, Q02085, Q08DS3, Q0IHB8, Q0P4W9, Q0VDQ9, Q25C93, Q28G88, Q2TAR3, Q2VWH6, Q32NK7, Q3MHQ4, Q3T135, Q3UH06, Q567J8, Q5T0B9, Q5VTD9, Q5XJQ7, Q60636, Q62255, Q66JF8, Q6AY34, Q6DBW0, Q6NRM0, Q804Q5

Diamond homologs: B0K011, E9Q6W4, P23803, P41995, P86413, Q08DS3, Q0IHB8, Q32NK7, Q3T135, Q567J8, Q5XJQ7, Q62255, Q66JF8, Q6AY34, Q7PN68, Q8I7Z8, Q8N2R0, Q8TAX0, Q8WUU4, Q91ZD1, Q9BXA9, Q9N5X6, Q9UJQ4, Q9VQS6, Q9VQS7, Q9VQU9, Q9WVG7, B0X9H6, O75362, O77459, P28698, P31509, P60319, P80944, Q01798, Q02026, Q02027, Q292R5, Q29419, Q3US17

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1728 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:19352356:G:C	F240L	1.000
2:19352356:G:T	F240L	1.000
2:19352357:A:G	F240S	1.000
2:19352358:A:G	F240L	1.000
2:19353145:G:C	H221D	1.000
2:19353153:A:G	L218P	1.000
2:19353170:G:C	F212L	1.000
2:19353170:G:T	F212L	1.000
2:19353171:A:G	F212S	1.000
2:19353172:A:G	F212L	1.000
2:19353184:A:G	C208R	1.000
2:19353193:A:G	C205R	1.000
2:19353215:G:C	H197Q	1.000
2:19353215:G:T	H197Q	1.000
2:19353222:C:G	R195P	1.000
2:19353229:G:C	H193D	1.000
2:19353229:G:T	H193N	1.000
2:19353237:A:G	L190P	1.000
2:19353254:G:C	F184L	1.000
2:19353254:G:T	F184L	1.000
2:19353255:A:G	F184S	1.000
2:19353256:A:G	F184L	1.000
2:19353267:C:T	C180Y	1.000
2:19353268:A:G	C180R	1.000
2:19353277:A:G	C177R	1.000
2:19352331:G:C	H249D	0.999
2:19352331:G:T	H249N	0.999
2:19352357:A:C	F240C	0.999
2:19352370:A:G	C236R	0.999
2:19352379:A:G	C233R	0.999

dbSNP variants (sampled 300 via entrez): RS1000044354 (2:19349774 C>T), RS1000115812 (2:19348432 C>G), RS1000178360 (2:19344662 C>T), RS1000522411 (2:19345801 G>C), RS1000595919 (2:19346077 T>C), RS1000627897 (2:19346238 A>G), RS1000928751 (2:19345135 T>C), RS1001234363 (2:19347772 G>A,C), RS1001312727 (2:19344965 A>C), RS1001332478 (2:19350686 A>G), RS1001345533 (2:19356957 T>C), RS1001384180 (2:19345211 T>C), RS1001659457 (2:19350460 A>G), RS1001696742 (2:19353021 A>G), RS1001885948 (2:19357544 GGACA>G)

Disease associations

OMIM: gene MIM:608891 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Disputed Evidence	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Disputed	AD

Mondo (1): congenital heart disease (MONDO:0005453)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST003274_3	Pulse pressure	8.000000e-12
GCST003991_8	Childhood ear infection	2.000000e-10
GCST003996_38	Monobrow	3.000000e-17
GCST004775_15	Pulse pressure	1.000000e-06
GCST005013_30	Childhood ear infection	2.000000e-10
GCST006108_3	Facial morphology	7.000000e-08
GCST006108_5	Facial morphology	3.000000e-08
GCST007096_145	Pulse pressure	5.000000e-24
GCST007097_155	Pulse pressure	7.000000e-06
GCST007099_252	Systolic blood pressure	8.000000e-09
GCST010479_55	Coronary artery disease	1.000000e-13
GCST010866_30	Coronary artery disease	7.000000e-29
GCST010867_26	Coronary artery disease	7.000000e-07
GCST010867_27	Coronary artery disease	2.000000e-14

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0007904	susceptibility to childhood ear infection measurement
EFO:0007906	synophrys measurement
EFO:0004743	facial morphology
EFO:0006335	systolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523406 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds).

Molecule	Name	Phase	Patents
CHEMBL5314346	VERTEPORFIN	4

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.72	IC50	19.1	nM	STAUROSPORINE
7.21	IC50	61.3	nM	STAUROSPORINE
6.70	IC50	200	nM	VERTEPORFIN

PubChem BioAssay actives

2 with measured affinity, of 49 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715237: Inhibition of human OSR1 using RRHYYYDTHTNTYYLRTFGHNTRR as substrate by [gamma-33P]-ATP assay	ic50	0.0191	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	affects expression, decreases methylation, increases expression	4
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
ferrous chloride	decreases expression	1
aflatoxin B2	increases methylation	1
polyhexamethyleneguanidine	increases response to substance	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Ethanol	decreases expression, increases abundance, affects cotreatment	1
Arsenic	increases methylation	1
Aspirin	increases expression	1
Cadmium	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Cytarabine	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Gasoline	decreases expression, increases abundance, affects cotreatment	1
Methapyrilene	increases methylation	1
Methotrexate	increases expression	1
Nickel	decreases expression	1

ChEMBL screening assays

40 unique, capped per target: 40 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4327806	Binding	Inhibition of human OSR1 assessed as residual activity at 1 uM using RRHYYYDTHTNTYYLRTFGHNTRR as substrate by [gamma-33P]-ATP assay relative to control	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. — Eur J Med Chem

Cellosaurus cell lines

6 cell lines: 3 embryonic stem cell, 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A5A2	SEES3-1V human OSR1, clone1	Embryonic stem cell	Male
CVCL_A5A3	SEES3-1V human OSR1, clone2	Embryonic stem cell	Male
CVCL_A5A4	SEES3-1V human OSR1, clone3	Embryonic stem cell	Male
CVCL_TB64	HAP1 OSR1 (-) 1	Cancer cell line	Male
CVCL_TB65	HAP1 OSR1 (-) 2	Cancer cell line	Male
CVCL_TB66	HAP1 OSR1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE